Wnt1 is an Lrp5-independent bone-anabolic Wnt ligand

Wnt1 is a physiologically relevant bone-anabolic molecule that does not require the expression of the bone-anabolic Wnt co-receptor Lrp5. Building bone Wnt signaling is important for proper embryonic development, shaping cell fate and migration, stem cell renewal, and organ and tissue formation. Here, Luther et al. investigated the role of Wnt1 in osteoporosis. Patients with early-onset osteoporosis and with WNT1 mutations had low bone turnover and high fracture rates, and loss of Wnt1 activity caused fracture and osteoporosis in mice. Inducing Wnt1 in bone-forming cells increased bone mass in aged mice, and this process did not require Lrp5, a co-receptor involved in Wnt signaling. This study identifies Wnt1 as an anabolic (bone building) factor and suggests that it might be a therapeutic target for osteoporosis. WNT1 mutations in humans are associated with a new form of osteogenesis imperfecta and with early-onset osteoporosis, suggesting a key role of WNT1 in bone mass regulation. However, the general mode of action and the therapeutic potential of Wnt1 in clinically relevant situations such as aging remain to be established. Here, we report the high prevalence of heterozygous WNT1 mutations in patients with early-onset osteoporosis. We show that inactivation of Wnt1 in osteoblasts causes severe osteoporosis and spontaneous bone fractures in mice. In contrast, conditional Wnt1 expression in osteoblasts promoted rapid bone mass increase in developing young, adult, and aged mice by rapidly increasing osteoblast numbers and function. Contrary to current mechanistic models, loss of Lrp5, the co-receptor thought to transmit extracellular WNT signals during bone mass regulation, did not reduce the bone-anabolic effect of Wnt1, providing direct evidence that Wnt1 function does not require the LRP5 co-receptor. The identification of Wnt1 as a regulator of bone formation and remodeling provides the basis for development of Wnt1-targeting drugs for the treatment of osteoporosis.

[1]  C. Ambrose,et al.  Osteocyte-specific WNT1 regulates osteoblast function during bone homeostasis , 2017, The Journal of clinical investigation.

[2]  T. Sajobi,et al.  Sex‐ and Site‐Specific Normative Data Curves for HR‐pQCT , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  O. Mäkitie,et al.  Teriparatide Treatment in Patients With WNT1 or PLS3 Mutation-Related Early-Onset Osteoporosis: A Pilot Study , 2016, The Journal of clinical endocrinology and metabolism.

[4]  Serge Ferrari,et al.  Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis , 2016, Therapeutic advances in musculoskeletal disease.

[5]  B. Williams Genetically engineered mouse models to evaluate the role of Wnt secretion in bone development and homeostasis , 2016, American journal of medical genetics. Part C, Seminars in medical genetics.

[6]  S. Khosla,et al.  Osteoclast TGF‐β Receptor Signaling Induces Wnt1 Secretion and Couples Bone Resorption to Bone Formation , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  M. Amling,et al.  The Anti‐Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5 , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  M. Djuric,et al.  Age- and Sex-Specific Bone Structure Patterns Portend Bone Fragility in Radii and Tibiae in Relation to Osteodensitometry: A High-Resolution Peripheral Quantitative Computed Tomography Study in 385 Individuals. , 2015, The journals of gerontology. Series A, Biological sciences and medical sciences.

[9]  C. Ambrose,et al.  The swaying mouse as a model of osteogenesis imperfecta caused by WNT1 mutations. , 2014, Human molecular genetics.

[10]  T. Schinke,et al.  Relevance of Wnt signaling for osteoanabolic therapy , 2014, Molecular and Cellular Therapies.

[11]  J. David,et al.  Inhibition of Bone Remodeling in Young Mice by Bisphosphonate Displaces the Plasma Cell Niche into the Spleen , 2014, The Journal of Immunology.

[12]  D. Graves,et al.  Non-canonical Wnt4 prevents skeletal aging and inflammation by inhibiting NF-κB , 2014, Nature Medicine.

[13]  Jacques P. Brown,et al.  Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. , 2014, Canadian family physician Medecin de famille canadien.

[14]  S. Ettenberg,et al.  Reversing LRP5‐Dependent Osteoporosis and SOST Deficiency–Induced Sclerosing Bone Disorders by Altering WNT Signaling Activity , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  A. Robling,et al.  Sclerostin Inhibition Reverses Skeletal Fragility in an Lrp5-Deficient Mouse Model of OPPG Syndrome , 2013, Science Translational Medicine.

[16]  Hang Lee,et al.  Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial , 2013, The Lancet.

[17]  Cassandra R Diegel,et al.  Lrp5 and Lrp6 Exert Overlapping Functions in Osteoblasts during Postnatal Bone Acquisition , 2013, PloS one.

[18]  R. Gibbs,et al.  WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. , 2013, The New England journal of medicine.

[19]  S. Mundlos,et al.  Mutations in WNT1 cause different forms of bone fragility. , 2013, American journal of human genetics.

[20]  A. Hess,et al.  PPARβ/δ governs Wnt signaling and bone turnover , 2013, Nature Medicine.

[21]  F. Glorieux,et al.  Mutations in WNT1 are a cause of osteogenesis imperfecta , 2013, Journal of Medical Genetics.

[22]  M. Amling,et al.  Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin , 2013, The Journal of cell biology.

[23]  Roland Baron,et al.  WNT signaling in bone homeostasis and disease: from human mutations to treatments , 2013, Nature Medicine.

[24]  H. Xu,et al.  LRP5 and LRP6 in development and disease , 2013, Trends in Endocrinology & Metabolism.

[25]  J. Kanis,et al.  Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  T. Martin,et al.  Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis , 2012, Nature Medicine.

[27]  P. Sambrook,et al.  Antiresorptive therapies for osteoporosis: a clinical overview , 2012, Nature Reviews Endocrinology.

[28]  B. Williams,et al.  Lrp5 and Lrp6 play compensatory roles in mouse intestinal development , 2012, Journal of cellular biochemistry.

[29]  B. Williams,et al.  Lrp5 and Lrp6 redundantly control skeletal development in the mouse embryo. , 2011, Developmental biology.

[30]  F. Mseeh,et al.  Lrp5 functions in bone to regulate bone mass , 2011, Nature Medicine.

[31]  T. Rachner,et al.  Osteoporosis: now and the future , 2011, The Lancet.

[32]  G. Sauter,et al.  Control of bone formation by the serpentine receptor Frizzled-9 , 2011, The Journal of cell biology.

[33]  C. Schiff,et al.  Osteoclast activity modulates B-cell development in the bone marrow , 2011, Cell Research.

[34]  Heather M. Macdonald,et al.  Age‐related patterns of trabecular and cortical bone loss differ between sexes and skeletal sites: A population‐based HR‐pQCT study , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  J. David,et al.  The multiple faces of autoimmune-mediated bone loss , 2010, Nature Reviews Endocrinology.

[36]  J. David,et al.  Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. , 2010, Cell metabolism.

[37]  A. Brivanlou,et al.  APCDD1 is a novel Wnt inhibitor mutated in hereditary hypotrichosis simplex , 2010, Nature.

[38]  M. Amling,et al.  Bone mineralization defects and vitamin D deficiency: Histomorphometric analysis of iliac crest bone biopsies and circulating 25‐hydroxyvitamin D in 675 patients , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  J. John Mann,et al.  Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum , 2008, Cell.

[40]  Hans Clevers,et al.  Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. , 2005, Developmental cell.

[41]  Walter Birchmeier,et al.  Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. , 2005, Developmental cell.

[42]  Xizhi Guo,et al.  Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. , 2005, Developmental cell.

[43]  M. Bouxsein,et al.  Decreased BMD and Limb Deformities in Mice Carrying Mutations in Both Lrp5 and Lrp6 , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[44]  J. A. Robinson,et al.  High Bone Mass in Mice Expressing a Mutant LRP5 Gene , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[45]  Jennifer J Westendorf,et al.  Lymphoid Enhancer Factor-1 and β-Catenin Inhibit Runx2-dependent Transcriptional Activation of the Osteocalcin Promoter* , 2003, The Journal of Biological Chemistry.

[46]  Jens Bollerslev,et al.  Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. , 2003, American journal of human genetics.

[47]  Robert D Cardiff,et al.  Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. , 2003, Genes & development.

[48]  Richard P Lifton,et al.  High bone density due to a mutation in LDL-receptor-related protein 5. , 2002, The New England journal of medicine.

[49]  Ivan Lobov,et al.  Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor , 2002, The Journal of cell biology.

[50]  J. Vahle,et al.  Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety , 2002, Toxicologic pathology.

[51]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[52]  M Dioszegi,et al.  Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). , 2001, Human molecular genetics.

[53]  E. Wagner,et al.  Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1 , 2000, Nature Medicine.

[54]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[55]  W. Reith,et al.  Conditional gene targeting in macrophages and granulocytes using LysMcre mice , 1999, Transgenic Research.

[56]  Harold E. Varmus,et al.  Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome , 1982, Cell.

[57]  D. Graves,et al.  Wnt 4 signaling prevents skeletal aging and inflammation by inhibiting nuclear factor-B , 2015 .

[58]  B. Clarke,et al.  Bone Mineralization Defects and Vitamin D Deficiency: Histomorphometric Analysis of Iliac Crest Bone Biopsies and Circulating 25-Hydroxyvitamin D in 675 Patients , 2010 .

[59]  A. McMahon,et al.  Noncanonical Wnt signaling through G protein-linked PKCdelta activation promotes bone formation. , 2007, Developmental cell.

[60]  Mark L. Johnson,et al.  A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. , 2002, American journal of human genetics.

[61]  P. Dineen,et al.  Now and in the future. , 1970, AORN journal.